Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 1/2015

01-01-2015 | Review Article

Indian Society of Gastroenterology consensus statements on Crohn’s disease in India

Authors: Balakrishnan S. Ramakrishna, Govind K. Makharia, Vineet Ahuja, Uday C. Ghoshal, Venkataraman Jayanthi, Benjamin Perakath, Philip Abraham, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra Desai, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Mathew Philip, Anna Pulimood, Amarender S. Puri, Gautam Ray, Shivaram P. Singh, Ajit Sood, Venkatraman Subramanian, Indian Society of Gastroenterology Task Force on Inflammatory Bowel Diseases

Published in: Indian Journal of Gastroenterology | Issue 1/2015

Login to get access

Abstract

In 2012, the Indian Society of Gastroenterology’s Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on Crohn’s disease (CD). This consensus, produced through a modified Delphi process, reflects our current recommendations for the diagnosis and management of CD in India. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.
Literature
1.
Ramakrishna BS, Makharia GK, Abraham P, et al. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol. 2012;31:307–23.
2.
3.
Periodic Health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.
4.
Tandon HD, Prakash A. Pathology of intestinal tuberculosis and its distinction from Crohn’s disease. Gut. 1972;13:260–9.PubMedCentralPubMed
5.
Das SK, Montgomery RD. Chronic inflammatory bowel disease in Asian immigrants. Practitioner. 1978;221:747–9.PubMed
6.
Walker AR, Segal I. Epidemiology of noninfective intestinal diseases in various ethnic groups in South Africa. Isr J Med Sci. 1979;15:309–13.PubMed
7.
8.
Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn’s disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34:1547–51.PubMedCentralPubMed
9.
Jayanthi V, Probert CS, Pinder D, Wicks AC, Mayberry JF. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. Q J Med. 1992;82:125–38.PubMed
10.
Probert CS, Jayanthi V, Pollock DJ, Baithun SI, Mayberry JF, Rampton DS. Crohn’s disease in Bangladeshis and Europeans in Britain: an epidemiological comparison in Tower Hamlets. Postgrad Med J. 1992;68:914–20.PubMedCentralPubMed
11.
Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Asian ethnic origin and the risk of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:543–6.PubMed
12.
Pinsk V, Lemberg DA, Grewal K, Barker CC, Schreiber RA, Jacobson K. Inflammatory bowel disease in the South Asian pediatric population of British Columbia. Am J Gastroenterol. 2007;102:1077–83.PubMed
13.
14.
Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17:2702–7.PubMedCentralPubMed
15.
Danda D, Kurian G, Chacko A, et al. Crohn’s disease in rheumatology clinic—an Indian experience. J Postgrad Med. 2005;51:269–72.PubMed
16.
Pugazhendhi S, Sahu MK, Subramanian V, Pulimood A, Ramakrishna BS. Environmental factors associated with Crohn’s disease in India. Indian J Gastroenterol. 2011;30:264–9.PubMed
17.
Goel A, Dutta AK, Pulimood AB, Eapen A, Chacko A. Clinical profile and predictors of disease behavior and surgery in Indian patients with Crohn’s disease. Indian J Gastroenterol. 2013;32:184–9.PubMed
18.
Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31:299–306.PubMed
19.
Baskaran K, Pugazhendhi S, Ramakrishna BS. Association of IRGM gene mutations with inflammatory bowel disease in the Indian population. PLoS One. 2014;9:e106863.PubMedCentralPubMed
20.
Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn’s disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci. 2009;54:1099–107.PubMed
21.
Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000;19:17–20.PubMed
22.
Amarapurkar DN, Patel ND, Rane PS. Diagnosis of Crohn’s disease in India where tuberculosis is widely prevalent. World J Gastroenterol. 2008;14:741–6.PubMedCentralPubMed
23.
Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu Rev Med. 2007;58:401–16.PubMed
24.
Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106:699–712.PubMed
25.
Juyal G, Amre D, Midha V, Sood A, Seidman E, Thelma BK. Evidence of allelic heterogeneity for associations between the NOD2/CARD15 gene and ulcerative colitis among North Indians. Aliment Pharmacol Ther. 2007;26:1325–32.PubMed
26.
Pugazhendhi S, Amte A, Balamurugan R, Subramanian V, Ramakrishna BS. Common NOD2 mutations are absent in patients with Crohn’s disease in India. Indian J Gastroenterol. 2008;27:201–3.PubMed
27.
Mahurkar S, Banerjee R, Rani VS, et al. Common variants in NOD2 and IL23R are not associated with inflammatory bowel disease in Indians. J Gastroenterol Hepatol. 2011;26:694–9.
28.
Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.PubMed
29.
Pulimood AB, Ramakrishna BS, Kurian G, Mathan VI, Mathan M. Endoscopic mucosal biopsies are useful in distinguishing granulomatous colitis due to Crohn’s disease from tuberculosis. Gut. 1999;45:537–41.PubMedCentralPubMed
30.
Pulimood A, Peter S, Ramakrishna BS, Kurian G. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn’s disease. J Gastroenterol Hepatol. 2005;20:688–96.PubMed
31.
Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis. 2010;4:63–101.
32.
Ramadass B, Chittaranjan S, Subramanian V, Ramakrishna BS. Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn’s disease from intestinal tuberculosis. Indian J Gastroenterol. 2010;29:152–6.PubMed
33.
Makharia GK, Srivastava S, Das P, et al. Clinical, endoscopic, and histological differentiations between Crohn’s disease and intestinal tuberculosis. Am J Gastroenterol. 2010;105:642–51.PubMed
34.
Dutta AK, Sahu MK, Gangadharan SK, Chacko A. Distinguishing Crohn’s disease from intestinal tuberculosis—a prospective study. Trop Gastroenterol. 2011;32:204–9.PubMed
35.
Pulimood AB, Amarapurkar DN, Ghoshal U, et al. Differentiation of Crohn’s disease from intestinal tuberculosis in India in 2010. World J Gastroenterol. 2011;17:433–43.PubMedCentralPubMed
36.
Tony J, Sunilkumar K, Thomas V. Randomized controlled trial of DOTS versus conventional regime for treatment of ileocecal and colonic tuberculosis. Indian J Gastroenterol. 2008;27:19–21.PubMed
37.
Makharia GK, Agnihotri A, Ghoshal UC, et al. A comparison between efficacy of 6 months versus 9 months of intermittent anti-tuberculous therapy for abdominal tuberculosis (intestinal and peritoneal): a randomized controlled trial. Indian J Gastroenterol. 2014;33 Suppl 1:A18.
38.
Nienhaus A, Schablon A, Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection—analysis of discordant results, when compared to the tuberculin skin test. PLoS One. 2008;3:e2665.PubMedCentralPubMed
39.
Lee JN, Ryu DY, Park SH, et al. The usefulness of in vitro interferon-gamma assay for differential diagnosis between intestinal tuberculosis and Crohn’s disease. Korean J Gastroenterol. 2010;55:376–83.PubMed
40.
Kim YS, Kim YH, Kim WH, et al. Diagnostic utility of anti-Saccharomyces cerevisiae antibody (ASCA) and Interferon-γ assay in the differential diagnosis of Crohn’s disease and intestinal tuberculosis. Clin Chim Acta. 2011;412:1527–32.PubMed
41.
Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340–55.PubMed
42.
Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn’s disease and intestinal tuberculosis in India. J Postgrad Med. 2007;53:166–70.PubMed
43.
Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosis. Dig Dis Sci. 2007;52:33–9.PubMed
44.
Kim KM, Lee A, Choi KY, Lee KY, Kwak JJ. Intestinal tuberculosis: clinicopathologic analysis and diagnosis by endoscopic biopsy. Am J Gastroenterol. 1998;93:606–9.PubMed
45.
Gan HT, Chen YQ, Ouyang Q, Bu H, Yang XY. Differentiation between intestinal tuberculosis and Crohn’s disease in endoscopic biopsy specimens by polymerase chain reaction. Am J Gastroenterol. 2002;97:1446–51.PubMed
46.
Amarapurkar DN, Patel ND, Amarapurkar AD, Agal S, Baigal R, Gupte P. Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn’s disease. J Assoc Physicians India. 2004;52:863–7.PubMed
47.
Pulimood AB, Peter S, Rook GW, Donoghue HD. In situ PCR for Mycobacterium tuberculosis in endoscopic mucosal biopsy specimens of intestinal tuberculosis and Crohn’s disease. Am J Clin Pathol. 2008;129:846–51.PubMed
48.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A.
49.
Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.PubMed
50.
Annunziata ML, Caviglia R, Papparella LG, Cicala M. Upper gastrointestinal involvement of Crohn’s disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012;57:1618–23.PubMed
51.
Hummel TZ, ten Kate FJ, Reitsma JB, Benninga MA, Kindermann A. Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. J Pediatr Gastroenterol Nutr. 2012;54:753–7.PubMed
52.
Jin XJ, Kim JM, Kim HK, et al. Histopathology and TB-PCR kit analysis in differentiating the diagnosis of intestinal tuberculosis and Crohn’s disease. World J Gastroenterol. 2010;16:2496–503.PubMedCentralPubMed
53.
Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn’s disease. Am J Gastroenterol. 2006;101:954–64.PubMed
54.
Pasha SF, Leighton JA, Das A, et al. Double-balloon enteroscopy and capsule endoscopy have comparable diagnostic yield in small-bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2008;6:671–6.PubMed
55.
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.PubMed
56.
Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43 10 Suppl:S85–93.
57.
Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–30.PubMed
58.
Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–63.PubMed
59.
Walters TD, Steinhart AH, Bernstein CN, et al. Validating Crohn’s disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis. 2011;17:1547–56.PubMed
60.
Korelitz BI, Sommers SC. Response to drug therapy in Crohn’s disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol. 1984;6:123–7.PubMed
61.
D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology. 1997;112:1475–81.PubMed
62.
Mandel MD, Miheller P, Müllner K, Golovics PA, Lakatos PL. Have biologics changed the natural history of Crohn’s disease? Dig Dis. 2014;32:351–9.PubMed
63.
Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn’s disease. Clin Gastroenterol Hepatol. 2015; 13:539–47.
64.
Dai C, Liu WX, Jiang M, Sun MJ. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One. 2014;9:e110797.PubMedCentralPubMed
65.
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–74.PubMed
66.
Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotherapy. 2012;32:515–26.PubMed
67.
Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;12:CD008870.PubMed
68.
Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617–29.PubMed
69.
Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-Aminosalicylic acid (mesalazine) use in Crohn’s disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis. 2007;13:1009–15.PubMed
70.
Sung JJ, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183–93.PubMed
71.
Duricova D, Pedersen N, Elkjaer M, Jensen JK, Munkholm P. 5-aminosalicylic acid dependency in Crohn’s disease: a Danish Crohn colitis database study. J Crohns Colitis. 2010;4:575–81.PubMed
72.
Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2–25.PubMed
73.
McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs. 2002;62:2263–82.PubMed
74.
Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97:1748–54.PubMed
75.
Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli budesonide study group. Gastroenterology. 1998;115:835–40.PubMed
76.
Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–9.PubMed
77.
Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.PubMed
78.
Summers RW, Switz DM, Sessions JT  Jr, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77:847–69.
79.
Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.PubMed
80.
Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–2.PubMedCentralPubMed
81.
Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;2:CD006792.PubMed
82.
McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.PubMed
83.
Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;6:CD000545.PubMed
84.
Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;4:CD000545.PubMed
85.
Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn’s disease. Indian J Gastroenterol. 2008;27:195–200.PubMed
86.
Benjamin J, Makharia G, Ahuja V, Joshi YK. Body composition in Indian patients with Crohn’s disease during active and remission phase. Trop Gastroenterol. 2011;32:285–91.PubMed
87.
Shamir R. Nutrition and growth in inflammatory bowel disease. World Rev Nutr Diet. 2013;106:156–61.PubMed
88.
Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr. 2013;32:904–10.PubMed
89.
Bermejo F, Garrido E, Chaparro M, et al. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn’s disease: are antibiotics enough? Inflamm Bowel Dis. 2012;18:1509–14.PubMed
90.
de Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA. Abdominal abscess in Crohn’s disease: multidisciplinary management. Dig Dis. 2014;32 Suppl 1:103–9.PubMed
91.
Lobatón T, Guardiola J, Rodriguez-Moranta F, et al. Comparison of the long-term outcome of two therapeutic strategies for the management of abdominal abscess complicating Crohn’s disease: percutaneous drainage or immediate surgical treatment. Colorectal Dis. 2013;15:1267–72.PubMed
92.
van Deen WK, van Oijen MG, Myers KD, et al. A nationwide 2010–2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747–53.PubMed
93.
Schoepfer AM, Bortolotti M, Pittet V, et al. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;40:930–7.PubMed
94.
Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630–42.PubMed
95.
Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;1:CD000067.PubMed
96.
Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD002913.PubMed
97.
French H, Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis. Dig Dis Sci. 2011;56:1929–36.PubMed
98.
99.
Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol. 2014;20:3198–207.PubMedCentralPubMed
100.
101.
Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149–57.PubMed
102.
Anstey AV, Wakelin S, Reynolds NJ. British association of dermatologists therapy, guidelines and audit subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004;151:1123–32.PubMed
103.
104.
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–59.PubMed
105.
Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci. 2013;9:765–79.PubMedCentralPubMed
106.
Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–62.PubMed
107.
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53.PubMed
108.
Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014;109:1443–9.PubMed
109.
Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975–81.PubMed
110.
Prevention Committee of the Japanese Society for Tuberculosis, Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. Kekkaku. 2014;89:21–37.
111.
Chen CH, Shu KH, Ho HC, et al. A nationwide population-based study of the risk of tuberculosis in different solid organ transplantations in Taiwan. Transplant Proc. 2014;46:1032–5.PubMed
112.
Hadaya K, Bridevaux PO, Roux-Lombard P, et al. Contribution of interferon-γ release assays (IGRAs) to the diagnosis of latent tuberculosis infection after renal transplantation. Transplantation. 2013;95:1485–90.PubMed
113.
Ferguson TW, Tangri N, Macdonald K, et al. The diagnostic accuracy of tests for latent tuberculosis infection in hemodialysis patients: a systematic review and meta-analysis. Transplantation. 2014 Oct 3.
114.
Cristaldi M, Sampietro GM, Danelli PG, Bollani S, Bianchi Porro G, Taschieri AM. Long-term results and multivariate analysis of prognostic factors in 138 consecutive patients operated on for Crohn’s disease using “bowel-sparing” techniques. Am J Surg. 2000;179:266–70.PubMed
115.
Mortara G, Ghirardi M, Prati M, et al. Surgical treatment of inflammatory bowel diseases in northwestern Italy: a multicentric study by the G.S.M.I.I. (inflammatory bowel disease study group). Ann Ital Chir. 2003;74:319–26.PubMed
116.
Walker DG, Williams HR, Kane SP, et al. Differences in inflammatory bowel disease phenotype between South Asians and Northern Europeans living in North West London, UK. Am J Gastroenterol. 2011;106:1281–9.PubMed
117.
Prakash K, Varma D, Mahadevan P, Narayanan RG, Philip M. Surgical treatment for small bowel Crohn’s disease: an experience of 28 cases. Indian J Gastroenterol. 2008;27:12–5.PubMed
118.
Forbes A. Crohn’s disease: rehabilitation after resection. Dig Dis. 2014;32:395–8.PubMed
119.
120.
Erkelens GW, van Deventer SJ. Endoscopic treatment of strictures in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2004;18:201–7.PubMed
121.
Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1457–64.PubMed
122.
Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:151–8.PubMed
123.
Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–92.PubMed
124.
Sordo-Mejia R, Gaertner WB. Multidisciplinary and evidence-based management of fistulizing perianal Crohn’s disease. World J Gastrointest Pathophysiol. 2014;5:239–51.PubMedCentralPubMed
125.
Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn’s disease. Aliment Pharmacol Ther. 2014;40:741–9.PubMed
126.
Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.PubMed
127.
Chebli JM, Gaburri PD, Chebli LA, et al. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit. 2014;20:487–98.PubMedCentralPubMed
128.
Campins M, Cossio Y, Martínez X, Borruel N. Vaccination of patients with inflammatory bowel disease. Practical recommendations. Rev Esp Enferm Dig. 2013;105:93–102.PubMed
129.
Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–6.PubMed
130.
Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn’s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173–8.PubMed
131.
Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014;30:168–74.PubMed
132.
Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:235–41.
133.
Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014;12:32–44.PubMed
134.
Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMed
135.
Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–87.PubMedCentralPubMed
136.
Rosenfeld G, Bressler B. Mycobacterium avium paratuberculosis and the etiology of Crohn’s disease: a review of the controversy from the clinician’s perspective. Can J Gastroenterol. 2010;24:619–24.PubMedCentralPubMed
137.
Singh AV, Singh SV, Singh PK, Sohal JS. Is Mycobacterium avium subsp. paratuberculosis, the cause of Johne’s disease in animals, a good candidate for Crohn’s disease in man? Indian J Gastroenterol. 2010;29:53–8.PubMed
138.
Liverani E, Scaioli E, Cardamone C, Dal Monte P, Belluzzi A. Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn’s disease, cause or epiphenomenon? World J Gastroenterol. 2014;20:13060–70.PubMedCentralPubMed
139.
Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology. 2007;132:2313–9.PubMed
140.
Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501–12.PubMed
141.
Hatch Q, Champagne BJ, Maykel JA, et al. The impact of pregnancy on surgical Crohn disease: an analysis of the Nationwide Inpatient Sample. J Surg Res. 2014;190:41–6.PubMed
142.
Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–8.PubMed
143.
Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76–84.PubMed
144.
Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.PubMed
145.
Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2014 Nov 5.
146.
Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis. 2014;8:1308–14.PubMed
147.
Laass MW, Straub S, Chainey S, Virgin G, Cushway T. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol. 2014;14:184.PubMedCentralPubMed
148.
Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–22.
149.
Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a Phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–88.
Metadata
Title
Indian Society of Gastroenterology consensus statements on Crohn’s disease in India
Authors
Balakrishnan S. Ramakrishna
Govind K. Makharia
Vineet Ahuja
Uday C. Ghoshal
Venkataraman Jayanthi
Benjamin Perakath
Philip Abraham
Deepak K. Bhasin
Shobna J. Bhatia
Gourdas Choudhuri
Sunil Dadhich
Devendra Desai
Bhaba Dev Goswami
Sanjeev K. Issar
Ajay K. Jain
Rakesh Kochhar
Goundappa Loganathan
Sri Prakash Misra
C. Ganesh Pai
Sujoy Pal
Mathew Philip
Anna Pulimood
Amarender S. Puri
Gautam Ray
Shivaram P. Singh
Ajit Sood
Venkatraman Subramanian
Indian Society of Gastroenterology Task Force on Inflammatory Bowel Diseases
Publication date
01-01-2015
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 1/2015
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-015-0539-6

Other articles of this Issue 1/2015

Indian Journal of Gastroenterology 1/2015 Go to the issue

Original Article

A study on the human pancreaticobiliary duct system and ampulla region with their clinical considerations

IMAGE

Endoscope captures immigrant tapes in duodenum

Original Article

Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype

LETTER

Primary epiploic appendagitis: Laparoscopic diagnosis and treatment

Original Article

A study of gender-wise risk association between fatty liver and metabolic syndrome components (Asia-Pacific criteria) in a South Indian urban cohort

Original Article

Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits